Supramolecular Tadalafil Nanovaccine for Cancer Immunotherapy by Alleviating Myeloid‐Derived Suppressor Cells and Heightening Immunogenicity

Small Methods ◽  
2021 ◽  
pp. 2100115
Author(s):  
Tian Zhang ◽  
Honggang Xiong ◽  
Xianbin Ma ◽  
Yuan Gao ◽  
Peng Xue ◽  
...  
2018 ◽  
Vol 67 (8) ◽  
pp. 1181-1195 ◽  
Author(s):  
Yijun Liu ◽  
Guowei Wei ◽  
Wesley A. Cheng ◽  
Zhenyuan Dong ◽  
Han Sun ◽  
...  

Biomaterials ◽  
2016 ◽  
Vol 96 ◽  
pp. 47-62 ◽  
Author(s):  
Maria Stella Sasso ◽  
Giovanna Lollo ◽  
Marion Pitorre ◽  
Samantha Solito ◽  
Laura Pinton ◽  
...  

Nano Today ◽  
2021 ◽  
Vol 39 ◽  
pp. 101163
Author(s):  
Xinghang Dai ◽  
Long Ren ◽  
Mengxi Liu ◽  
Hao Cai ◽  
Hu Zhang ◽  
...  

2016 ◽  
Vol 6 (1) ◽  
Author(s):  
Wei He ◽  
Pei Liang ◽  
Guangxing Guo ◽  
Zhen Huang ◽  
Yiming Niu ◽  
...  

Cells ◽  
2021 ◽  
Vol 10 (5) ◽  
pp. 1170
Author(s):  
Mithunah Krishnamoorthy ◽  
Lara Gerhardt ◽  
Saman Maleki Maleki Vareki

The primary function of myeloid cells is to protect the host from infections. However, during cancer progression or states of chronic inflammation, these cells develop into myeloid-derived suppressor cells (MDSCs) that play a prominent role in suppressing anti-tumor immunity. Overcoming the suppressive effects of MDSCs is a major hurdle in cancer immunotherapy. Therefore, understanding the mechanisms by which MDSCs promote tumor growth is essential for improving current immunotherapies and developing new ones. This review explores mechanisms by which MDSCs suppress T-cell immunity and how this impacts the efficacy of commonly used immunotherapies.


Sign in / Sign up

Export Citation Format

Share Document